Publications

Click THIS LINK for the latest list of our publications on PubMed​

Myerson JW, Patel PN, Habibi N, Walsh LR, Lee Y-W, Luther DC, Ferguson LT, Zaleski MH, Zamora ME, Marcos-Contreras OA, Glassman PM, Johnston I, Hood ED, Shuvaeva T, JV, Kiseleva RY, Nong J, Rubey KM, Greineder CF, Mitragotr S, Worthen GS, Rotello VM, Lahann J, Muzykantov VR, Brenner JS.  Supramolecular Organization Predicts Protein Nanoparticle Delivery to Neutrophils for Acute Lung Inflammation Diagnosis and Treatment.  Under review at Nature Nanotechnology.  bioRxiv: https://biorxiv.org/cgi/content/short/2020.04.15.037564v1
 

Glassman PM, Myerson JW, Ferguson LT, Kiseleva RY, Shuvaev VV, Brenner JS, Muzykantov VR. Targeting drug delivery in the vascular system: Focus on endothelium.  Adv Drug Deliv Rev. 2020 Jun 21:S0169-409X(20)30059-4. doi: 10.1016/j.addr.2020.06.013. PMID: 32579890
 

Glassman PM, Villa CH, Ukidve A, Zhao Z, Smith P, Mitragotri S, Russell AJ, Brenner JS, Muzykantov VR.  Vascular Drug Delivery Using Carrier Red Blood Cells: Focus on RBC Surface Loading and Pharmacokinetics. Pharmaceutics. 2020 May 9;12(5):440. doi: 10.3390/pharmaceutics12050440.  PMID: 32397513.
 

Marcos-Contreras OA, Greineder CF, Kiseleva RY, Parhiz H, Walsh LR, Zuluaga-Ramirez V, Myerson JW, Hood ED, Villa CH, Tombacz I, Pardi N, Seliga A, Mui BL, Tam YK, Glassman PM, Shuvaev VV, Nong J, Brenner JS, Khoshnejad M, Madden T, Weissmann D, Persidsky Y, Muzykantov VR.  Selective targeting of nanomedicine to inflamed cerebral vasculature to enhance the blood-brain barrier.  Proc Natl Acad Sci U S A. 2020 Feb 18;117(7):3405-3414. doi: 10.1073/pnas.1912012117.
 

Khoshnejad M, Brenner JS, Parhiz H, Muzykantov VR. CRISPR/Cas9-Mediated Genetic Engineering of Hybridomas for Creation of Antibodies that Allow for Site-Specific Conjugation. Methods Mol Biol. 2019;2033:81-93. doi: 10.1007/978-1-4939-9654-4_7.


Paris AJ, Guo L, Dai N, Katzen JB, Patel PN, Worthen GS, Brenner JS.  Using selective lung injury to improve murine models of spatially heterogeneous lung diseases.  PLoS One. 2019 Apr 3;14(4):e0202456. doi: 10.1371/journal.pone.0202456.
 

Marcos-Contreras OA, Brenner JS, Kiseleva RY, Zuluaga-Ramirez V, Greineder CF, Villa CH, Hood ED, Myerson JW, Muro S, Persidsky Y, Muzykantov VR.  Combining vascular targeting and the local first pass provides 100-fold higher uptake of ICAM-1-targeted vs untargeted nanocarriers in the inflamed brain.  J Control Release. 2019 May 11;301:54-61. doi: 10.1016/j.jconrel.2019.03.008.


Parhiz H, Shuvaev VV, Pardi N, Khoshnejad M, Kiseleva RY, Brenner JS, Uhler T, Tuyishime S, Mui BL, Tam YK, Madden TD, Hope MJ, Weissman D, Muzykantov VR.   PECAM-1 directed re-targeting of exogenous mRNA providing two orders of magnitude enhancement of vascular delivery and expression in lungs independent of apolipoprotein E-mediated uptake.  J Control Release. 2018 Dec 10;291:106-115. doi: 10.1016/j.jconrel.2018.10.015.
 

Muzykantov VR, Brenner JS.  Vascular Immunotargeting: Take the Highway to the First Exit. Hepatology. 2018 Nov;68(5):1672-1674. doi: 10.1002/hep.30141.

Brenner JS*, Pan D*, Myerson J*, Marcos-Contreras OA*, et al.  RBC-hitchhiking boosts delivery of nanocarriers to chosen organs by orders of magnitude.  Nature Communications. 2018 Jul 11;9(1):2684. doi: 10.1038/s41467-018-05079-7

Parhiz H, Khoshnejad M, Myerson JW, Hood E, Patel PN, Brenner JS, Muzykantov VR.  Unintended effects of drug carriers: Big issues of small particles.  Adv Drug Deliv Rev. 2018 May;130:90-112. doi: 10.1016/j.addr.2018.06.023.

Pan DC, Myerson JW, Brenner JS, Patel PN, Anselmo AC, Mitragotri S, Muzykantov V. Nanoparticle Properties Modulate Their Attachment and Effect on Carrier Red Blood Cells.  Sci Rep. 2018 Jan 25;8(1):1615. doi: 10.1038/s41598-018-19897-8.

Khoshnejad M*, Brenner JS*, Motley W, Parhiz H, Greineder CF, Villa CH, Marcos-Contreras OA, Tsourkas A, Muzykantov VR.  Molecular engineering of antibodies for site-specific covalent conjugation using CRISPR/Cas9. Sci Rep. 2018 Jan 29;8(1):1760. doi: 10.1038/s41598-018-19784-2.

Brenner JS, Kiseleva RY, Glassman PM, Parhiz H, Greineder CF, Hood ED, Shuvaev VV, Muzykantov VR. The new frontiers of the targeted interventions in the pulmonary vasculature: precision and safety (2017 Grover Conference Series).  Pulm Circ. 2018 Jan-Mar; 8(1): 2045893217752329. doi: 10.1177/2045893217752329.

Brenner JS.  Nanomedicine for the Treatment of Acute Respiratory Distress Syndrome. The 2016 ATS Bear Cage Award-winning Proposal.  Ann Am Thorac Soc. 2017 Apr;14(4):561-564. doi: 10.1513/AnnalsATS.201701-090PS.

 

Brenner JS, Bhamidipati K, Glassman P, Ramakrishnan N, Jiang D, Paris AJ, Myerson JW, Pan DC, Shuvaev VV, Villa C, Hood ED, Kiseleva R, Greineder CF, Radhakrishnan R, Muzykantov VR.

Mechanisms that determine nanocarrier targeting to healthy versus inflamed lung regions. Nanomedicine. 2017 Jan 5. pii: S1549-9634(16)30236-2. doi: 10.1016/j.nano.2016.12.019.

Paris AJ, Liu Y, Mei J, Dai N, Guo L, Spruce LA, Hudock KM, Brenner JS, Zacharias WJ, Mei HD, Slamowitz AR, Bhamidipati K, Beers MF, Seeholzer SH, Morrisey EE, Worthen GS.  Neutrophils promote alveolar epithelial regeneration by enhancing type II pneumocyte proliferation in a model of acid-induced acute lung injury.  Am J Physiol Lung Cell Mol Physiol. 2016 Dec 1;311(6):L1062-L1075. doi: 10.1152/ajplung.00327.2016.

 

Greineder CF, Hood ED, Yao A, Khoshnejad M, Brenner JS, Johnston IH, Poncz M, Gottstein C, Muzykantov VR. (2016) Molecular engineering of high affinity single-chain antibody fragment for endothelial targeting of proteins and nanocarriers in rodents and humans. J Control Release. 2016 Feb 6; 226: 229-237. doi: 10.1016/j.jconrel.2016.02.006

 

Brenner JS, Greineder C, Shuvaev V, Muzykantov V. (2015)  Endothelial nanomedicine for the treatment of pulmonary disease.  Expert Opin Drug Deliv. 2015 Feb;12(2):239-61. doi: 10.1517/17425247.2015.961418.

blah

©2020 by Brenner Bioengineering Lab